Scientists tracked insulin sprayed up the nose reaching the brain to fight Alzheimer’s.

For years, researchers investigating insulin as a potential Alzheimer’s treatment have faced a frustrating pattern: promising results in early trials followed by inconsistent outcomes when the approach moved to larger studies. One persistent question sat underneath all of it, unanswered by any of the earlier work. Nobody had directly confirmed, in living human brains, that insulin sprayed into the nose actually reached the regions of the brain most affected by Alzheimer’s disease in the first place.

A new imaging study set out to close that gap, using a specialized nasal delivery device and a radioactive tracer to watch, in real time, where the insulin actually went once it left the nasal cavity.

What the researchers did

The study, conducted by researchers at Wake Forest University School of Medicine and detailed in reporting from Inside Precision Medicine, recruited 16 older adults with an average age of 72, including seven participants who were cognitively normal and nine who had been diagnosed with mild cognitive impairment, often considered an early warning stage that can precede Alzheimer’s disease. Each participant received insulin through a specialized six-spray nasal device paired with a novel radiotracer, a compound called gallium-68-labeled NOTA-insulin, engineered specifically so researchers could track the insulin’s path using positron emission tomography, or PET, imaging.

Following administration, participants underwent 40-minute PET brain scans along with whole-body imaging, allowing the research team to map exactly where the labeled insulin accumulated inside the brain rather than relying on indirect measures like cognitive test scores or cerebrospinal fluid sampling, both of which had been the primary tools available to earlier researchers working on this question.

What the scans revealed

The imaging showed elevated insulin uptake across eleven distinct brain regions considered critical for memory and cognitive function, including the hippocampus, the amygdala, the temporal lobe and the olfactory cortex, the region located closest to the nasal cavity that has long been theorized as a likely entry point for nasally delivered compounds attempting to reach the brain. The hippocampus in particular carries outsized significance for Alzheimer’s research, since it is among the earliest brain structures to show measurable deterioration as the disease progresses, making direct evidence that nasally delivered insulin reaches that specific region a meaningfully different kind of finding than earlier, more indirect studies had been able to produce.

Notably, the imaging also revealed that uptake patterns differed depending on a participant’s cognitive status. Cognitively normal participants showed higher overall insulin uptake in the brain along with a slower clearance rate, meaning the insulin remained detectable in brain tissue for longer, while participants with mild cognitive impairment displayed different absorption patterns altogether. Researchers have not yet fully explained what drives that difference, though it raises the possibility that the brain’s ability to absorb and retain nasally delivered insulin may itself change as cognitive impairment develops, a detail that could eventually factor into how any future nasal insulin therapy is dosed or timed for different patient populations.

Why the safety data matters

Beyond confirming that the insulin reached its intended targets, the study also gathered safety data on the nasal delivery method itself, a necessary step before any therapy built around this delivery route could advance toward larger clinical trials. Only two of the sixteen participants reported any adverse effect, in both cases mild headaches that resolved within 24 hours, with no other significant side effects reported across the study group. That safety profile, while drawn from a small sample, is consistent with prior research suggesting nasal insulin delivery is generally well tolerated, and it supports moving the approach toward larger trials designed to test therapeutic effectiveness rather than simply confirming safety.

The research was published in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions, a peer-reviewed publication focused on bridging laboratory findings with clinical application in dementia research.

Why direct confirmation matters for a treatment already in testing

Intranasal insulin has been studied as a potential Alzheimer’s intervention for more than a decade, built on the theory that insulin resistance in the brain, sometimes described informally as a form of diabetes localized to brain tissue, may contribute to the cognitive decline seen in Alzheimer’s disease. Delivering insulin through the nose offers a theoretical advantage over other delivery routes because the nasal cavity connects relatively directly to structures near the front of the brain, potentially allowing the hormone to bypass the blood-brain barrier that blocks many drugs from reaching brain tissue when taken orally or through standard injection.

Earlier clinical trials testing this approach produced a mixed track record, with some studies reporting cognitive benefits and others failing to replicate those results, a pattern researchers have long suspected might stem partly from uncertainty about whether the insulin used in different trials was consistently reaching the brain regions it was intended to affect. Without imaging confirmation, researchers were left inferring delivery success indirectly, through cognitive outcomes or biomarker changes, rather than observing it directly.

What comes next

This study does not establish that nasal insulin treats or slows Alzheimer’s disease; it establishes something narrower but foundational, that the delivery mechanism itself functions as intended in a small group of older adults, reaching the specific brain regions where researchers hoped it would go. That distinction matters for how the finding should be interpreted. Confirming successful delivery is a prerequisite for meaningfully testing whether nasal insulin can affect cognitive outcomes, not a substitute for that larger question, which will require considerably bigger and longer trials to answer.

Researchers involved in the work have described the imaging results as providing a clearer foundation for designing future trials, potentially allowing investigators to better calibrate dosing and delivery schedules based on the uptake patterns observed here, including the apparent differences between cognitively normal participants and those with mild cognitive impairment. For a field that has spent years testing a promising but inconsistently performing intervention without being able to confirm exactly where the treatment was going once administered, having direct imaging evidence marks a meaningful methodological step forward, even as the central question of therapeutic effectiveness remains open for future research to answer.

Morning Overview produced this article with AI assistance and reviewed it against the cited sources.

More from Morning Overview